CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Danielson PB. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr. Drug Metab.3(6),561–597 (2002).
  Medline CASGoogle Scholar
• 2  Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev.54(10),1271–1294 (2002).
  Medline CASGoogle Scholar
• 3  Shimada T, Guengerich FP. Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl Acad. Sci. USA86(2),462–465 (1989).
  Medline CASGoogle Scholar
• 4  Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5´-upstream regulatory region. Biochem. Biophys. Res. Commun.259(1),201–205 (1999).
  Medline CASGoogle Scholar
• 5  Westlind-Johnsson A, Malmebo S, Johansson A et al. Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab. Dispos.31(6),755–761 (2003).
  Medline CASGoogle Scholar
• 6  Chiou WL, Jeong HY, Wu TC, Ma C. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization. Clin. Pharmacol. Ther.70(4),305–310 (2001).
  Medline CASGoogle Scholar
• 7  Mathijssen RH, Loos WJ, Verweij J. Determining the best dose for the individual patient. J. Clin. Oncol.29(33),4345–4346 (2011).
  MedlineGoogle Scholar
• 8  Ozdemir V, Kalow W, Tang BK et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics10(5),373–388 (2000).▪ Analysis suggesting that more than 90% of CYP3A4 variability has a genetic basis.
  Medline CASGoogle Scholar
• 9  Baker SD, van Schaik RH, Rivory LP et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin. Cancer Res.10(24),8341–8350 (2004).
  Medline CASGoogle Scholar
• 10  Ball SE, Scatina J, Kao J et al. Population distribution and effects on drug metabolism of a genetic variant in the 5´ promoter region of CYP3A4. Clin. Pharmacol. Ther.66(3),288–294 (1999).
  Medline CASGoogle Scholar
• 11  Floyd MD, Gervasini G, Masica AL et al. Genotype–phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European– and African–American men and women. Pharmacogenetics13(10),595–606 (2003).
  Medline CASGoogle Scholar
• 12  He P, Court MH, Greenblatt DJ, Von Moltke LL. Genotype–phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin. Pharmacol. Ther.77(5),373–387 (2005).
  Medline CASGoogle Scholar
• 13  Kharasch ED, Walker A, Isoherranen N et al. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam. Clin. Pharmacol. Ther.82(4),410–426 (2007).
  Medline CASGoogle Scholar
• 14  Lepper ER, Baker SD, Permenter M et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin. Cancer Res.11(20),7398–7404 (2005).
  Medline CASGoogle Scholar
• 15  Miao J, Jin Y, Marunde RL et al. Association of genotypes of the CYP3A cluster with midazolam disposition in vivo. Pharmacogenomics J.9(5),319–326 (2009).
  Medline CASGoogle Scholar
• 16  Shih PS, Huang JD. Pharmacokinetics of midazolam and 1´-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab. Dispos.30(12),1491–1496 (2002).
  Medline CASGoogle Scholar
• 17  Tomalik-Scharte D, Doroshyenko O, Kirchheiner J et al. No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam. Eur. J. Clin. Pharmacol.64(10),1033–1035 (2008).
  Medline CASGoogle Scholar
• 18  Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5´-promoter region polymorphism. Clin. Pharmacol. Ther.68(1),82–91 (2000).
  Medline CASGoogle Scholar
• 19  Wang D, Guo Y, Wrighton SA, Cooke GE, Sadee W. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J.11(4),274–286 (2011).▪▪ Original study describing the effect of the CYP3A4*22 allele on CYP3A4 activity and expression in the human liver.
  MedlineGoogle Scholar
• 20  Elens L, Becker ML, Haufroid V et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet. Genomics21(12),861–866 (2011).▪ Study showing that the CYP3A4*22 allele is associated with a better lipid-lowering response in simvastatin-treated patients.
  Medline CASGoogle Scholar
• 21  Elens L, Bouamar R, Hesselink DA et al. A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients. Clin. Chem.57(11),1574–1583 (2011).▪ Study showing that the CYP3A4*22 allele is associated with a lower tacrolimus dose requirement in kidney transplant patients.
  Medline CASGoogle Scholar
• 22  Elens L, Bouamar R, Hesselink DA, Haufroid V, van Gelder T, van Schaik RH. The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet. Genomics22(5),373–380 (2012).
  Medline CASGoogle Scholar
• 23  Elens L, van Schaik RH, Panin N et al. Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors’ dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics12(10),1383–1396 (2011).
  CASGoogle Scholar
• 24  Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin. Pharmacokinet.49(4),207–221 (2010).
  Medline CASGoogle Scholar
• 25  Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin. Pharmacokinet.49(3),141–175 (2010).
  Medline CASGoogle Scholar
• 26  Mathijssen RH, van Schaik RH. Genotyping and phenotyping cytochrome P450: perspectives for cancer treatment. Eur. J. Cancer42(2),141–148 (2006).
  Medline CASGoogle Scholar
• 27  Rogers JF, Rocci ML Jr, Haughey DB, Bertino JS Jr. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity. Clin. Pharmacol. Ther.73(3),153–158 (2003).
  Medline CASGoogle Scholar
• 28  Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics10(3),187–216 (2000).
  Medline CASGoogle Scholar
• 29  Gorski JC, Hall SD, Jones DR, Vandenbranden M, Wrighton SA. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol.47(9),1643–1653 (1994).
  Medline CASGoogle Scholar
• 30  He P, Court MH, Greenblatt DJ, von Moltke LL. Factors influencing midazolam hydroxylation activity in human liver microsomes. Drug Metab. Dispos.34(7),1198–1207 (2006).
  Medline CASGoogle Scholar
• 31  Patki KC, von Moltke LL, Greenblatt DJ. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes p450: role of CYP3A4 and CYP3A5. Drug Metab. Dispos.31(7),938–944 (2003).
  Medline CASGoogle Scholar
• 32  Rivory LP, Slaviero KA, Hoskins JM, Clarke SJ. The erythromycin breath test for the prediction of drug clearance. Clin. Pharmacokinet.40(3),151–158 (2001).
  Medline CASGoogle Scholar
• 33  Rivory LP, Watkins PB. Erythromycin breath test. Clin. Pharmacol. Ther.70(4),395–399 (2001).
  Medline CASGoogle Scholar
• 34  Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology20(2),309–316 (1994).
  Medline CASGoogle Scholar
• 35  Lown KS, Thummel KE, Benedict PE et al. The erythromycin breath test predicts the clearance of midazolam. Clin. Pharmacol. Ther.57(1),16–24 (1995).
  Medline CASGoogle Scholar
• 36  Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin. Pharmacol. Ther.52(5),471–478 (1992).
  Medline CASGoogle Scholar
• 37  Watkins PB. Noninvasive tests of CYP3A enzymes. Pharmacogenetics4(4),171–184 (1994).
  Medline CASGoogle Scholar
• 38  Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin. Pharmacol. Ther.48(2),120–129 (1990).
  Medline CASGoogle Scholar
• 39  Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O’Mara EM Jr, Hall SD. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther.64(2),133–143 (1998).
  Medline CASGoogle Scholar
• 40  Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. Pharmacol.36(1),89–96 (1989).
  Medline CASGoogle Scholar
• 41  Wandel C, Bocker R, Bohrer H, Browne A, Rugheimer E, Martin E. Midazolam is metabolized by at least three different cytochrome P450 enzymes. Br. J. Anaesth.73(5),658–661 (1994).
  Medline CASGoogle Scholar
• 42  Wrighton SA, Brian WR, Sari MA et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol.38(2),207–213 (1990).
  Medline CASGoogle Scholar
• 43  Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. The effect of an individual’s cytochrome CYP3A4 activity on docetaxel clearance. Clin. Cancer Res.6(4),1255–1258 (2000).
  Medline CASGoogle Scholar
• 44  Rivory LP, Slaviero K, Seale JP et al. Optimizing the erythromycin breath test for use in cancer patients. Clin. Cancer Res.6(9),3480–3485 (2000).
  Medline CASGoogle Scholar
• 45  van der Bol JM, Mathijssen RH, Creemers GJ et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin. Cancer Res.16(2),736–742 (2010).
  Medline CASGoogle Scholar
• 46  Mathijssen RH, de Jong FA, van Schaik RH et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J. Natl Cancer Inst.96(21),1585–1592 (2004).
  Medline CASGoogle Scholar
• 47  Chaobal HN, Kharasch ED. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam. Clin. Pharmacol. Ther.78(5),529–539 (2005).
  Medline CASGoogle Scholar
• 48  Kim JS, Nafziger AN, Tsunoda SM et al. Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. J. Clin. Pharmacol.42(4),376–382 (2002).
  Medline CASGoogle Scholar
• 49  Nguyen AN, Hoffman JT, Tsunoda SM, Jang IJ, Ma JD. Evaluation of intravenous midazolam limited sampling models to determine area under the concentration time curve during cytochrome P450 3A baseline, inhibition and induction or activation. Int. J. Clin. Pharmacol. Ther.50(7),468–475 (2012).
  Medline CASGoogle Scholar
• 50  Wong M, Balleine RL, Collins M, Liddle C, Clarke CL, Gurney H. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin. Pharmacol. Ther.75(6),529–538 (2004).
  Medline CASGoogle Scholar
• 51  Kurnik D, Wood AJ, Wilkinson GR. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin. Pharmacol. Ther.80(3),228–234 (2006).
  Medline CASGoogle Scholar
• 52  Lan LB, Dalton JT, Schuetz EG. Mdr1 limits CYP3A metabolism in vivo. Mol. Pharmacol.58(4),863–869 (2000).
  Medline CASGoogle Scholar